The estimated Net Worth of Christine Bellon is at least $2.75 Milhão dollars as of 1 April 2024. Dr Bellon owns over 3,401 units of Beam Therapeutics stock worth over $2,522,807 and over the last 2 years he sold BEAM stock worth over $230,475.
Dr has made over 6 trades of the Beam Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 3,401 units of BEAM stock worth $109,240 on 1 April 2024.
The largest trade he's ever made was exercising 10,000 units of Beam Therapeutics stock on 20 November 2023 worth over $72,200. On average, Dr trades about 3,341 units every 46 days since 2023. As of 1 April 2024 he still owns at least 104,594 units of Beam Therapeutics stock.
You can see the complete history of Dr Bellon stock trades at the bottom of the page.
Dr. Christine P. Bellon J.D., Ph.D. is the Sr. VP, Chief Legal Officer & Corp. Sec. at Beam Therapeutics.
Dr D is 55, he's been the Sr. VP e Chief Legal Officer & Corp. Sec. of Beam Therapeutics since . There are 5 older and 11 younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics Inc. is Mark Fishman, 68, who is the Independent Director.
Christine's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr, eKristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeutics executives and other stock owners filed with the SEC include: